BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cucinotta U, Dipasquale V, Costa S, Pellegrino S, Ramistella V, Romano C. Vedolizumab-associated pulmonary manifestations in children with ulcerative colitis. J Clin Pharm Ther 2021. [PMID: 34278581 DOI: 10.1111/jcpt.13494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Claßen M, de Laffolie J, Claßen M, Schnell A, Sohrabi K, Hoerning A. Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease - Data from the multicenter CEDATA-GPGE registry study. Front Pediatr 2022;10:903677. [PMID: 36304532 DOI: 10.3389/fped.2022.903677] [Reference Citation Analysis]
2 Schmid F, Chao C, Däbritz J. Pathophysiological Concepts and Management of Pulmonary Manifestation of Pediatric Inflammatory Bowel Disease. IJMS 2022;23:7287. [DOI: 10.3390/ijms23137287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 . Vedolizumab. Reactions Weekly 2022;1900:320-320. [DOI: 10.1007/s40278-022-12672-1] [Reference Citation Analysis]
4 Zhang J, Liu MH, Gao X, Dong C, Li YX. Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report. World J Clin Cases 2022; 10(5): 1716-1722 [DOI: 10.12998/wjcc.v10.i5.1716] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]